VERTEX PHARMACEUTICAL CEDEAR EACH 101 REPR 1 ORDVERTEX PHARMACEUTICAL CEDEAR EACH 101 REPR 1 ORDVERTEX PHARMACEUTICAL CEDEAR EACH 101 REPR 1 ORD

VERTEX PHARMACEUTICAL CEDEAR EACH 101 REPR 1 ORD

No trades
See on Supercharts

VRTX fundamentals

An in-depth look to VERTEX PHARMACEUTICAL CEDEAR EACH 101 REPR 1 ORD operating, investing, and financing activities

VRTX free cash flow for Q1 25 is 834.98 B ARS. For 2024, VRTX free cash flow was -814.74 B ARS and operating cash flow was -507.84 B ARS.

Q2 '17
Q3 '17
Q4 '17
Q1 '18
Q2 '18
Q3 '18
Q4 '18
Q1 '19
Q2 '19
Q3 '19
Q4 '19
Q1 '20
Q2 '20
Q3 '20
Q4 '20
Q1 '21
Q2 '21
Q3 '21
Q4 '21
Q1 '22
Q2 '22
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
Cash from operating activities
Cash from investing activities
Cash from financing activities
Currency: ARS
Q2 '17
Q3 '17
Q4 '17
Q1 '18
Q2 '18
Q3 '18
Q4 '18
Q1 '19
Q2 '19
Q3 '19
Q4 '19
Q1 '20
Q2 '20
Q3 '20
Q4 '20
Q1 '21
Q2 '21
Q3 '21
Q4 '21
Q1 '22
Q2 '22
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
TTM
Free cash flowYoY growth